Adalimumab

Adalimumab, an entirely human monoclonal antibody, specifically blocks the cell-surface receptor relationship of tumor necrosis factor-alpha (TNF-α) with p55 and p75 TNF-α, thereby suppressing the biological activity of TNF-α. It received FDA approval in 2008 for the treatment of moderate to severe psoriasis that does not respond to conventional treatments or for which these treatments are contraindicated or intolerable. Adalimumab is also indicated for the treatment of moderate to severe chronic plaque psoriasis in children aged 4 and over. Administered via subcutaneous injections, adalimumab is also suitable for intermittent use under certain conditions.

Adalimumab

Tamamý insan monoklonal antikoru olan adalimumab, spesifik olarak tümör nekroz faktörü-alfa (TNF-α) ile p55 ve p75 TNF-α hücre-yüzey reseptör iliþkisini bloke ederek, TNF-α’nýn biyolojik aktivitesini baskýlar. Konvansiyonel tedavilere yanýt vermeyen, bu tedavilerin kontrendike olduðu veya tolere edilemediði orta-þiddetli psoriasis tedavisinde 2008’de FDA onayý almýþtýr. Adalimumab, 4 yaþ ve üzeri çocuklarda da orta ve þiddetli kronik plak tip psoriasis tedavisinde endikedir. Subkütan enjeksiyonlar þeklinde uygulanan adalimumab, belli koþullarda aralýklý kullanýma da uygun bir ajandýr.